Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

zuellig pharma sdn bhd - cabozantinib (s)-malate -

Israel - English - Ministry of Health

bristol, myers squibb (israel) limited, israel - ipilimumab - concentrate for solution for infusion - ipilimumab 5 mg/ml - ipilimumab - ipilimumab - unresectable or metastatic melanomayervoy (ipilimumab) is indicated for the treatment of adult patients with advanced (unresectable or metastatic) melanoma. yervoy in combination with nivolumab is indicated for the treatment of adult and pediatric patients 12 years and older with advanced (unresectable or metastatic) melanoma . advanced renal cell carcinomayervoy, in combination with nivolumab, is indicated for the first-line treatment of adult patients with intermediate or poor risk, advanced renal cell carcinoma (rcc). microsatellite instability-high (msi-h) or mismatch repair deficient (dmmr) metastatic colorectal canceryervoy, in combination with nivolumab, is indicated for the treatment of adult and pediatric patients 12 years of age and older with microsatellite instability-high (msi-h) or mismatch repair deficient (dmmr) metastatic colorectal cancer (crc) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.metastatic non-small cell lung canceryervoy, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy, is indicated for the first-line treatment of adult patients with metastatic or recurrent non-small cell lung cancer (nsclc) with no egfr or alk genomic tumor aberrations.hepatocellular carcinomayervoy, in combination with nivolumab, is indicated for the treatment of adult patients with hepatocellular carcinoma (hcc) child-pugh a who have been previously treated with sorafenib.malignant pleural mesotheliomayervoy, in combination with nivolumab, is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesotheliomaesophageal canceryervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%.

Singapore - English - HSA (Health Sciences Authority)

ipsen pharma singapore pte. ltd. - cabozantinib (s)-malate 25.34mg eqv cabozantinib - tablet, film coated - cabozantinib (s)-malate 25.34mg eqv cabozantinib 20mg

Singapore - English - HSA (Health Sciences Authority)

ipsen pharma singapore pte. ltd. - cabozantinib (s)-malate 50.69mg eqv cabozantinib - tablet, film coated - cabozantinib (s)-malate 50.69mg eqv cabozantinib 40mg

Singapore - English - HSA (Health Sciences Authority)

ipsen pharma singapore pte. ltd. - cabozantinib (s)-malate 76.03mg eqv cabozantinib - tablet, film coated - cabozantinib (s)-malate 76.03mg eqv cabozantinib 60mg

Canada - English - Health Canada

bristol-myers squibb canada - ipilimumab - solution - 5mg - ipilimumab 5mg - antineoplastic agents

Singapore - English - HSA (Health Sciences Authority)

bristol-myers squibb (singapore) pte. ltd. - ipilimumab - injection, solution, concentrate - 5g - ipilimumab 5mg/ml

Ireland - English - HPRA (Health Products Regulatory Authority)

kora corporation limited trading as kora healthcare - magnesium - tablet - 97 milligram(s) - magnesium citrate

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

merck sdn. bhd. - avelumab -

Canada - English - Health Canada

ipsen biopharmaceuticals canada inc - cabozantinib (cabozantinib malate) - tablet - 20mg - cabozantinib (cabozantinib malate) 20mg - antineoplastic agents